Refining the treatment of NSCLC according to histological and molecular subtypes
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Refining the treatment of NSCLC according to histological and molecular subtypes
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 12, Issue 9, Pages 511-526
Publisher
Springer Nature
Online
2015-05-12
DOI
10.1038/nrclinonc.2015.90
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- (2015) Ariel Lopez-Chavez et al. JOURNAL OF CLINICAL ONCOLOGY
- Exceptional responders—discovering predictive biomarkers
- (2015) Naoko Takebe et al. Nature Reviews Clinical Oncology
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
- (2014) K. Azuma et al. ANNALS OF ONCOLOGY
- Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
- (2014) S.-H. I. Ou et al. ANNALS OF ONCOLOGY
- B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer
- (2014) Scott Gettinger et al. CANCER JOURNAL
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma
- (2014) Naamit K. Gerber et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance
- (2014) Kang-Seo Park et al. JOURNAL OF CLINICAL INVESTIGATION
- Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project
- (2014) Fiona H. Blackhall et al. JOURNAL OF CLINICAL ONCOLOGY
- Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of “Master Protocols” in Lung Cancer
- (2014) Shakun M. Malik et al. Journal of Thoracic Oncology
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
- (2014) Takashi Seto et al. LANCET ONCOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer
- (2014) Christine M Lovly et al. NATURE MEDICINE
- Acquired resistance to TKIs in solid tumours: learning from lung cancer
- (2014) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
- (2014) E. C. de Bruin et al. SCIENCE
- Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
- (2014) Y. Y. Janjigian et al. Cancer Discovery
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
- (2013) R. Dienstmann et al. ANNALS OF ONCOLOGY
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer
- (2013) M. A. Socinski et al. CLINICAL CANCER RESEARCH
- A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320
- (2013) Paul W. Sperduto et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
- (2013) Deborah A. Knight et al. JOURNAL OF CLINICAL INVESTIGATION
- Designing Transformative Clinical Trials in the Cancer Genome Era
- (2013) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?
- (2013) Tony Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
- (2013) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- New Targetable Oncogenes in Non–Small-Cell Lung Cancer
- (2013) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
- (2013) Kadoaki Ohashi et al. JOURNAL OF CLINICAL ONCOLOGY
- LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both
- (2013) Nobuyuki Katakami et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
- (2013) Neal I. Lindeman et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
- (2013) Yi-Long Wu et al. LANCET ONCOLOGY
- Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer
- (2013) Jean-Louis Pujol et al. LUNG CANCER
- The quest to overcome resistance to EGFR-targeted therapies in cancer
- (2013) Curtis R Chong et al. NATURE MEDICINE
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
- (2013) Luc Friboulet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
- (2013) Jim Sang et al. Cancer Discovery
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma
- (2012) A. Thomas et al. ANNALS OF ONCOLOGY
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
- (2012) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- RETFusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
- (2012) Rui Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2012) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapies for non-small-cell lung cancer and mesothelioma
- (2012) Anish Thomas et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
- (2012) Julian R. Molina et al. MAYO CLINIC PROCEEDINGS
- The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
- (2012) Y. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib
- (2011) Y. Y. Janjigian et al. CLINICAL CANCER RESEARCH
- Impact of tumour volume on the potential efficacy of therapeutic vaccines
- (2011) J. L. Gulley et al. Current Oncology
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
- (2011) Y. S. Ju et al. GENOME RESEARCH
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- (2011) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
- (2011) C. Grommes et al. NEURO-ONCOLOGY
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
- (2010) S. Heon et al. CLINICAL CANCER RESEARCH
- Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
- (2010) Geoffrey R. Oxnard et al. CLINICAL CANCER RESEARCH
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer
- (2009) Alessandra Bearz et al. LUNG CANCER
- Targeted Therapies to Improve Tumor Immunotherapy
- (2008) J. Begley et al. CLINICAL CANCER RESEARCH
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- (2008) Jean-Pierre Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023
- (2008) Karen Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation